Literature DB >> 8206747

Intravenous immunoglobulin, plasmalymphocytapheresis and azathioprine in chronic progressive multiple sclerosis.

A Uccelli1, E Capello, D Fenoglio, M Incagliato, M Valbonesi, G L Mancardi.   

Abstract

Five patients with a severe form of chronic progressive multiple sclerosis no longer responsive to steroid therapy were treated for six months with high-dose intravenous immunoglobulin associated with plasmalymphocytapheresis and azathioprine. In spite of an apparent initial stabilization of the course of the disease, EDSS assessment after six and twelve months of therapy revealed progressive disability in all patients.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8206747     DOI: 10.1007/bf02343496

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  2 in total

Review 1.  Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis.

Authors:  Laura E Baldassari; Robert J Fox
Journal:  Drugs       Date:  2018-10       Impact factor: 11.431

Review 2.  Diagnosis and Management of Progressive Multiple Sclerosis.

Authors:  Gabrielle Macaron; Daniel Ontaneda
Journal:  Biomedicines       Date:  2019-07-29
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.